The present study assessed the interaction of propranolol with antipyrine, a compound that shares with many other drugs a primary biotransformation pathway involving hydroxylation by the liver.1`I As such, the pharmacokinetic profile of antipyrine is extensively used as an index of drugmetabolizing capacity in humans, and appears to be sensitive to factors that stimulate or inhibit drug metabolism.
Analysis of Samples
Plasma concentrations of antipyrine were determined by spectrophotometric assay.4 I Urinary excretion of unchanged antipyrine and of its metabolite, 4-hydroxyantipyrine, were determined by gas chromatography using acetaminophen as an internal standard.-The presence of propranolol in plasma did not interfere with the assay for antipyrine. Analysis of Data
For each subject-trial, the slope of the terminal log-linear 50-portion of the plot of antipyrine plasma concentration versus time was determined by least-squares regression analysis. The slope and intercept of the least-squares line was used to 30-determine the antipyrine elimination half-life, volume of dis0°t ribution, and clearance.8 Differences in these variables 20- -b between the control and propranolol conditions were analyzed using Student's paired t-test.
The degree of beta adrenergic sensitivity (or blockade) was determined from a graph of the increase in ventricular -0 rate over the pre-isoproterenol baseline value versus the logarithm of the isoproterenol dose. The slope and intercept of 6 \ this line were used to determine the 30-beat chronotropic SUBJECT 3 dose (CD-30). fig. 2 ). In addition, the -40 24-hour urinary excretion of 4-hydroxyantipyrine ( fig. 3) fell   0 . ,, from a mean of 23.6 ± 4.9% of the dose during the control period to 14.8 + 0.8% during propranolol treatment (paired t= 1.86, 0.1 < P < 0.2). There was also a trend toward an 20-increase in the 24-hour urinary excretion of unchanged antipyrine during the propranolol trial (from 3.9 + 0.6 to 4.7 ± 0.8% of the dose). None of the changes in the pharmacokinetic variables was correlated with the beta blockade 10 index.
Discussion

5X
Administration of therapeutic doses of propranolol to -healthy individuals in the present study had no apparent \ effect upon the volume of distribution of a single intravenous SUBJECT 6 dose of antipyrine, but significantly prolonged antipyrine elimination half-life, and significantly reduced its total 20.0 The exact mechanism of the propranolol-antipyrine interaction is not established by our study. Assuming hepatic blood flow in a healthy individual to be approximately 21 ml/kg/min, the hepatic extraction ratio for antipyrine, estimated as the ratio of its clearance divided by hepatic blood flow,8 12 averaged only about 4% in the control state. Thus, although propranolol has the ability to reduce cardiac output and hepatic blood flow in healthy individuals,12 it is unlikely that a change in hepatic blood flow could account for the reduction in antipyrine clearance attributable to propranolol.', 14 A previous report in fact indicated that the clearance of morphine, a compound with a much higher hepatic extraction ratio than that of antipyrine, was not influenced by propranolol.15 It is therefore likely that propranolol has a direct influence on the activity of the hepatic microsomal enzymes responsible for drug hydroxylation.'8 Further studies on the mechanism and clinical implications of this interaction are necessary. Studies are also needed to establish the time-course of interaction following propranolol discontinuation, since we assessed only those effects attributable to concurrent propranolol treatment.
